scholarly journals Markers of Endothelial Activation and Impaired Autonomic Function in Patients with Acute Coronary Syndromes – Potential Prognostic and Therapeutic Implication

10.5772/28250 ◽  
2012 ◽  
Author(s):  
Arman Postadzhiyan ◽  
Anna Tzontcheva ◽  
Bojidar Finkov
Keyword(s):  
Acute Coronary Syndromes ◽  
Autonomic Function ◽  
Endothelial Activation ◽  
Therapeutic Implication ◽  
Coronary Syndromes

Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes

2003 ◽  
Vol 14 (6) ◽  
pp. 563-567 ◽  
Author(s):  
Victor L Serebruany ◽  
Alexander H Glassman ◽  
Alex I Malinin ◽  
David C Sane ◽  
Mitchell S Finkel ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
Endothelial Activation ◽  
Depressed Patients ◽  
Coronary Syndromes

scholarly journals Effect of Conventional and More Aggressive Rosuvastatin Treatment on Markers of Endothelial Activation

2008 ◽  
Vol 27 (4) ◽  
pp. 432-438 ◽  
Author(s):  
Arman Postadzhiyan ◽  
Anna Tzontcheva ◽  
Ivan Kehajov ◽  
Stanimir Kyurkchiev ◽  
Margarita Apostolova ◽  
...  
Keyword(s):  
Adhesion Molecule ◽  
Acute Coronary Syndromes ◽  
Serum Levels ◽  
Endothelial Activation ◽  
Treated Group ◽  
Intercellular Adhesion Molecule ◽  
Intercellular Adhesion Molecule 1 ◽  
St Segment Elevation ◽  
St Segment ◽  
Coronary Syndromes

Effect of Conventional and More Aggressive Rosuvastatin Treatment on Markers of Endothelial ActivationTreatment of hypercholesterolemia with HMG-CoA reductase inhibitors results in an earlier reduction of morbidity and mortality than expected from trials using conventional cholesterol-lowering therapies. Possible explanations for this effect include improvement of endothelial function, plaque stabilization, and inhibition of the inflammatory response associated with atherosclerosis. In this study we assessed the effects of low and moderate dose rosuvastatin treatment, on circulating markers of endothelial activation in patients admitted for acute coronary syndromes without ST segment elevation. Thirty patients with unstable angina and non ST segment elevation myocardial infarction were rando - mized into two groups, and received rosuvastatin 10 mg/day (n =16) or rosuvastatin 20 mg/day (n =14) for 12 weeks. Circulating levels of soluble vascular cell adhesion molecule (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) were measured at admission, and at the end of the study. Lipid values were significantly reduced in both treatment groups, but with significantly greater reduction in the aggressively treated group. Serum levels of sICAM-1 and sVCAM-1 were significantly decreased in both rosuvastatin-treated groups during 12 weeks of follow-up with a more pronounced decrease in the more aggressively treated group. Therefore, rosuvastatin modulates endothelial activation in patients after acute coronary syndromes.

Sign in / Sign up

Export Citation Format

Share Document